TargetDrug

TargetDrug (Shanghai) Co., Ltd. is a clinical-stage biotechnology company based in Shanghai, China, that operates as the drug discovery and development arm of Tigermed. Founded in 2002, the company specializes in the development of small molecule therapeutics for infectious diseases, particularly HIV and Hepatitis C. Its lead research programs have focused on CCR5 antagonists, including the candidates Nifeviroc (TD-0232) and TD-0680, which aim to block viral entry into host cells. TargetDrug has engaged in high-profile international collaborations with organizations such as the Australian biotech Avexa and the University of Hong Kong to advance its pipeline. While some of its early clinical programs faced setbacks or were discontinued, the company remains a significant entity within the Tigermed group's broader pharmaceutical innovation strategy.